ライフサイエンスコーパス: zalcitabine

1 idovudine combined with either didanosine or zalcitabine.

2 dovudine plus didanosine, or zidovudine plus zalcitabine.

3 day) or zidovudine plus either saquinavir or zalcitabine.

4 ent with zidovudine and either saquinavir or zalcitabine.

5 A double-blind phase II trial compared zalcitabine (0.03 mg/kg/day) in combination with zidovud

6 ical use, two are modified cytosine analogs, Zalcitabine (2',3'-dideoxycytidine (ddC)) and Lamivudine

7 peritoneally, exhibited antinociception in a zalcitabine (2'-3'-dideoxycytidine) model of AIDS therap

8 y) plus both zidovudine (600 mg per day) and zalcitabine (2.25 mg per day) or zidovudine plus either

9 azard ratio, 0.50; P<0.001), zidovudine plus zalcitabine (20 percent; relative hazard ratio, 0.54; P<

10 susceptibility to group 2 drugs (didanosine, zalcitabine, abacavir, and lamivudine) decreased.

11 mma-DNA complex bound to either substrate or zalcitabine, an inhibitor used for HIV reverse transcrip

12 ither saquinavir and zidovudine (P=0.017) or zalcitabine and zidovudine (P<0.001).

13 ne alone, 0.77 (P=0.085) for zidovudine plus zalcitabine, and 0.69 (P=0.019) for didanosine alone.

14 rcent of the 367 assigned to zidovudine plus zalcitabine, and 66 percent of the 372 assigned to zidov

15 resistance (3-fold to 5-fold) to didanosine, zalcitabine, and stavudine.

16 Treatment with saquinavir, zalcitabine, and zidovudine was well tolerated.

17 ERV RT to lamivudine, stavudine, didanosine, zalcitabine, and zidovudine were reduced >20-fold, 26-fo

18 The structures reveal that zalcitabine binds to the Pol gamma active site almost id

19 g over 6 orders of magnitude in the sequence zalcitabine (ddC) > didanosine (ddI metabolized to ddA)

20 patients treated with zidovudine (AZT) plus zalcitabine (ddC) and didanosine (ddI) develop AZT resis

21 with zidovudine (Zdv), didanosine (ddI), or zalcitabine (ddC) was acceptable.

22 IC(50) values for Zdv, zalcitabine (ddC), didanosine (ddI), 3TC, and stavudine

23 V), cytarabine (Ara-C), zidovudine (AZT) and zalcitabine (ddC)-we show that TDP1 is capable of removi

24 are due to some of the antiretroviral drugs (zalcitabine, didanosine or stavudine).

25 children enrolled in a prospective trial of zalcitabine (dideoxycytidine) monotherapy (Pediatric AID

26 the high-dose lamivudine groups than for the zalcitabine group (median changes at 52 weeks were +42.5

27 dine group, and -0.39 log10 copies/mL in the zalcitabine group).

28 amivudine group, and -29.58 cells/mm3 in the zalcitabine group).

29 plus 200 mg of zidovudine three times daily (zalcitabine group).

30 ervations of NRTIs, abacavir, stavudine, and zalcitabine increased HIV-1 mutation frequencies, suppor

31 apy with zidovudine and either didanosine or zalcitabine is not superior to zidovudine therapy alone.

32 effects, and treatment with zidovudine plus zalcitabine, more neuropathy.

33 t forcing tumor glycolysis in melanoma using zalcitabine or other similar approaches may be an adjunc

34 tial combination therapy with zidovudine and zalcitabine or zidovudine and didanosine would delay the

35 to combination therapy (adding didanosine or zalcitabine) or sequential monotherapy (changing to dida

36 zidovudine plus didanosine, zidovudine plus zalcitabine, or didanosine alone slows the progression o

37 re randomized to zidovudine, zidovudine plus zalcitabine, or zidovudine plus didanosine.

38 nosine; 600 mg of zidovudine plus 2.25 mg of zalcitabine; or 400 mg of didanosine.

39 anosine, and 0.89+/-0.06 for zidovudine plus zalcitabine (P<0.001 for each of the pairwise comparison

40 (high-dose lamivudine group); or 0.75 mg of zalcitabine plus 200 mg of zidovudine three times daily

41 d the three-drug combination (zidovudine and zalcitabine plus saquinavir) were codon 48 alone in 1.4%

42 ogic evidence of benefit than did 0.75 mg of zalcitabine plus zidovudine and was better tolerated tha

43 omplex with substrate or antiviral inhibitor zalcitabine provide a basis for understanding Pol gamma-

44 Knowledge of the low incidence of zalcitabine resistance and the switch from SI to NSI phe

45 nce of syncytium-inducing (SI) phenotype and zalcitabine resistance.

46 Only 1 child (3%) developed zalcitabine resistance.

47 ntial monotherapy (changing to didanosine or zalcitabine) significantly improves survival.

48 nhibited by tenofovir, abacavir, lamivudine, zalcitabine, stavudine, and zidovudine.

49 For zidovudine plus zalcitabine, the benefits were limited to those without

50 Thus, administration of zidovudine with zalcitabine to children with prior zidovudine treatment

51 tilized the FDA-approved antiretroviral drug zalcitabine to suppress mitochondrial respiration and to

52 After >44 weeks of zalcitabine treatment, the SI and NSI phenotypes were ma

53 microM at baseline and 0.18 microM following zalcitabine treatment.

54 to 1.03), and treatment with zidovudine plus zalcitabine was associated with a relative risk of 0.92

55 eatment with the anti-retroviral agent, ddC (Zalcitabine) with or without the concomitant delivery of